Search

Your search keyword '"Bang, Lia"' showing total 567 results

Search Constraints

Start Over You searched for: Author "Bang, Lia" Remove constraint Author: "Bang, Lia"
567 results on '"Bang, Lia"'

Search Results

1. A randomized trial of low-dose thrombolysis, ultrasound-assisted thrombolysis, or heparin for intermediate-high risk pulmonary embolism—the STRATIFY trial: design and statistical analysis plan

2. Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

3. Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

9. Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study

10. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network

14. Comparison of Effect of Ischemic Postconditioning on Cardiovascular Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention With Versus Without Thrombectomy

15. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity.

16. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes.

18. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

19. Half-Life and Clearance of Cardiac Troponin I and Troponin T in Humans.

20. Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial.

21. Usefulness of High Sensitivity Troponin T to Predict Long-Term Left Ventricular Dysfunction After ST-Elevation Myocardial Infarction

23. Electrocardiogram to predict reperfusion success in late presenters with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

24. Rare and low-frequency coding variants alter human adult height

25. Effect of Alirocumab on Carotid Inflammation by [18F]FDG PET in Patients with Acute Myocardial Infarction

27. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

28. Effect of Alirocumab on Carotid Inflammation by [18F]FDG PET in Patients With Acute Myocardial Infarction

29. Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T):study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

30. Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial):study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

31. Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction:The PULSE-MI Randomized Clinical Trial

32. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

33. Brain Health After COVID-19, Pneumonia, Myocardial Infarction, or Critical Illness

36. High Lipoprotein(a) May Explain One-Quarter of Clinical Familial Hypercholesterolemia Diagnoses in Danish Lipid Clinics

37. Kinetics of cardiac troponin and other biomarkers in patients with ST elevation myocardial infarction

38. Coronary CT Angiography as a Guide to Timing of Invasive Treatment in Patients With NSTEACS

39. High Lipoprotein(a) May Explain One-Quarter of Clinical Familial Hypercholesterolemia Diagnoses in Danish Lipid Clinics.

40. Admission Leukocyte Count is Associated with Late Cardiogenic Shock Development and All-Cause 30-Day Mortality in Patients with St-Elevation Myocardial Infarction

41. Dr. Galen Wagner (1939-2016) as an Academic Writer: An Overview of his Peer-reviewed Scientific Publications

42. Pre-Hospital Pulse Glucocorticoid Therapy in Patients with ST-Segment Elevation Myocardial Infarction Transferred for Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (PULSE-MI)

45. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial

46. Lactate is a Prognostic Factor in Patients Admitted With Suspected ST-Elevation Myocardial Infarction

47. Pre-hospital pulse glucocorticoid therapy in patients with ST-segment elevation myocardial infarction transferred for primary percutaneous coronary intervention:a randomized controlled trial (PULSE-MI)

48. Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics:Danish national study

49. Kinetics of cardiac troponin and other biomarkers in patients with ST elevation myocardial infarction

50. Brain Health After COVID-19, Pneumonia, Myocardial Infarction, or Critical Illness

Catalog

Books, media, physical & digital resources